Literature DB >> 2688073

Benign polyarthritis and undifferentiated arthritis an epidemiological terra incognita.

H Zeidler1, J L Hülsemann.   

Abstract

Introduction of new diagnostic criteria and the development of HLA-typing and microbiological--serological techniques have aided in classifying and differentiating inflammatory rheumatic diseases. Reviewing epidemiological prevalence studies shows that inflammatory rheumatic diseases are often so called benign polyarthritides and that arthritides, classified as definite and probable rheumatoid arthritis (RA), may belong to a group of benign or undifferentiated arthritides. Own data show that only 25% of patients of an early synovitis out-patient clinic have definite or probable RA, 25% have an undifferentiated arthritis. The term "undifferentiated" refers to the heterogeneity of diseases included. We conclude that few epidemiologic studies exist concerning undifferentiated arthritis and spondarthritis and combined efforts are needed to distinguish RA from the multitude of other well characterized or yet unknown arthritides.

Entities:  

Mesh:

Year:  1989        PMID: 2688073     DOI: 10.3109/03009748909092607

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  3 in total

1.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  B Combe; R Landewe; C Lukas; H D Bolosiu; F Breedveld; M Dougados; P Emery; G Ferraccioli; J M W Hazes; L Klareskog; K Machold; E Martin-Mola; H Nielsen; A Silman; J Smolen; H Yazici
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 2.  Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis.

Authors:  Lisa G Suter; Liana Fraenkel; R Scott Braithwaite
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-05       Impact factor: 4.794

3.  Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort.

Authors:  Marloes Verstappen; Xanthe M E Matthijssen; Annette H M van der Helm-van Mil
Journal:  Rheumatology (Oxford)       Date:  2022-08-03       Impact factor: 7.046

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.